Synergy of TLR4 agonist GSK1795091, an innate immune activator, with agonistic antibody against co-stimulatory immune checkpoint molecule OX40 in cancer immunotherapy.

Hua-Xin Gao,Sabyasachi Bhattacharya,Christopher Matheny,Niranjan Yanamandra,Shu-Yun Zhang,Heidi Emerich,Yufeng Li,Paul Bojczuk,Hong Shi,Wei Wang,Christopher B. Hopson,Tihui Fu,James P. Allison,Padmanee Sharma,James Smothers,Roopa Srinivasan,Axel Hoos

Synergy of TLR4 agonist GSK1795091, an innate immune activator, with agonistic antibody against co-stimulatory immune checkpoint molecule OX40 in cancer immunotherapy.

2018

Hua-Xin Gao
Sabyasachi Bhattacharya
Christopher Matheny
Niranjan Yanamandra
Shu-Yun Zhang
Heidi Emerich
Yufeng Li
Paul Bojczuk
Hong Shi
Wei Wang
Christopher B. Hopson
Tihui Fu
James P. Allison
Padmanee Sharma
James Smothers
Roopa Srinivasan
Axel Hoos

12055Background: GSK1795091 (aka, GSK’091) is a synthetic glycolipid toll-like receptor 4 (TLR4) agonist. TLR4 is a Pattern Recognition Receptor for host defense against bacterial infection, expres...

Keywords:

Agonistic behaviour
Antibody
Cancer immunotherapy
Innate immune system
Activator (genetics)
Cancer research
Pathology
TLR4 Agonist GSK1795091
Medicine
Immune checkpoint
Agonist
Receptor
TLR4
Pattern recognition receptor

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations